Document Type: Original Article

Authors

1 Department of Neurology, School of Medicine, Sari Branch, Islamic Azad University, Sari, Iran

2 Department of Neurology, School of Medicine, Qom Branch, Islamic Azad University, Qom, Iran

3 Department of Neurology, School of Medicine, Tehran Branch, Islamic Azad University, Tehran, Iran

4 Neuroscience Research Center, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

5 Department of Mechanical Engineering, College of Engineering, Temple University, Philadelphia, USA

6 Department of Neurology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Abstract

Background: Multiple sclerosis (MS) is one of the most common autoimmune diseases worldwide and various autoimmune comorbidities are reported with MS. The objective of this study is to estimate the prevalence of the autoimmune diseases’ comorbidity in patients with MS.
Methods: In this cross-sectional study, we investigated a group of patients with MS in terms of age, gender, duration of MS, presence of simultaneous autoimmune diseases, such as Graves’ disease, Hashimoto’s thyroiditis, type 1 diabetes mellitus (DM), and systemic lupus erythematous (SLE).
Results: This study included 1215 patients with MS, of which 70.8% were women. The mean age of participants was 33.70 ± 27.63 years. 55 patients (4.5%) had at least one autoimmune disease. The most common comorbidity was for Hashimoto’s thyroiditis (30 patients). The frequency of simultaneous autoimmune disease was higher in women. Mean age (P = 0.01), mean duration of MS (P = 0.03), and mean age on MS diagnosis (P = 0.02) were significantly higher in simultaneous MS and other autoimmune diseases.
Conclusion: Our study revealed that the probability of autoimmune diseases co-occurrence in patients with MS could be higher in older patients, in longer duration of disease, and also in patients with higher age at time of MS diagnosis.

Keywords

  1. Wingerchuk DM, Lucchinetti CF, Noseworthy JH. Multiple sclerosis: Current pathophysiological concepts. Lab Invest 2001; 81(3): 263-81.
  2. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol 2000; 47(6): 707-17.
  3. Lassmann H, Bruck W, Lucchinetti CF. The immunopathology of multiple sclerosis: An overview. Brain Pathol 2007; 17(2): 210-8.
  4. Tullman MJ. Overview of the epidemiology, diagnosis, and disease progression associated with multiple sclerosis. Am J Manag Care 2013; 19(2 Suppl): S15-S20.
  5. Wu GF, Alvarez E. The immunopathophysiology of multiple sclerosis. Neurol Clin 2011; 29(2): 257-78.
  6. Sadovnick AD, Ebers GC, Dyment DA, Risch NJ. Evidence for genetic basis of multiple sclerosis. The Canadian Collaborative Study Group. Lancet 1996; 347(9017): 1728-30.
  7. Marrie RA, Cohen J, Stuve O, Trojano M, Sorensen PS, Reingold S, et al. A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview. Mult Scler 2015; 21(3): 263-81.
  8. Magyari M, Koch-Henriksen N, Pfleger CC, Sorensen PS. Gender and autoimmune comorbidity in multiple sclerosis. Mult Scler 2014; 20(9): 1244-51.
  9. Olsson T, Zhi WW, Hojeberg B, Kostulas V, Jiang YP, Anderson G, et al. Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-gamma. J Clin Invest 1990; 86(3): 981-5.
  10. Karni A, Abramsky O. Association of MS with thyroid disorders. Neurology 1999; 53(4): 883-5.
  11. Pelidou SH, Tsifetaki N, Giannopoulos S, Deretzi G, Voulgari P, Kyritsis A. Multiple sclerosis associated with systemic sclerosis. Rheumatol Int 2007; 27(8): 771-3.
  12. Noseworthy JH, Bass BH, Vandervoort MK, Ebers GC, Rice GP, Weinshenker BG, et al. The prevalence of primary Sjogren's syndrome in a multiple sclerosis population. Ann Neurol 1989; 25(1): 95-8.
  13. Kinnunen E, Jarvinen P, Ketonen L, Sepponen R. Co-twin control study on cerebral manifestations of systemic lupus erythematosus. Acta Neurol Scand 1993; 88(6): 422-6.
  14. Mpofu S, Moots RJ. A case of multiple sclerosis associated with rheumatoid arthritis and positive anticardiolipin antibodies. Ann Rheum Dis 2003; 62(4): 376.
  15. Pelidou SH, Giannopoulos S, Tzavidi S, Tsifetaki N, Kitsos G, Stefanou D, et al. Neurological manifestations of connective tissue diseases mimicking multiple sclerosis. Rheumatol Int 2007; 28(1): 15-20.
  16. Sahraian MA, Owji M, Naser MA. Concomitant multiple sclerosis and another autoimmune disease: Does the clinical course change? Clin Neurol Neurosurg 2016; 150: 92-5.
  17. Zivadinov R, Raj B, Ramanathan M, Teter B, Durfee J, Dwyer MG, et al. Autoimmune comorbidities are associated with brain injury in multiple sclerosis. AJNR Am J Neuroradiol 2016; 37(6): 1010-6.
  18. Lorefice L, Fenu G, Pitzalis R, Scalas G, Frau J, Coghe G, et al. Autoimmune comorbidities in multiple sclerosis: What is the influence on brain volumes? A case-control MRI study. J Neurol 2018; 265(5): 1096-101.
  19. Freedman MS, Thompson EJ, Deisenhammer F, Giovannoni G, Grimsley G, Keir G, et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol 2005; 62(6): 865-70.
  20. Ioppoli C, Meucci G, Mariotti S, Martino E, Lippi A, Gironelli L, et al. Circulating thyroid and gastric parietal cell autoantibodies in patients with multiple sclerosis. Ital J Neurol Sci 1990; 11(1): 31-6.
  21. Annunziata P, Lore F, Venturini E, Morana P, Guarino E, Borghi S, et al. Early synthesis and correlation of serum anti-thyroid antibodies with clinical parameters in multiple sclerosis. J Neurol Sci 1999; 168(1): 32-6.
  22. Dal-Bianco A, Wenhoda F, Rommer PS, Weber M, Altmann P, Kraus J, et al. Do elevated autoantibodies in patients with multiple sclerosis matter? Acta Neurol Scand 2019; 139(3): 238-46.
  23. Belniak E, Stelmasiak Z, Papuc E. Multiple sclerosis and other autoimmune diseases. Neurol Neurochir Pol 2007; 41(3): 259-66. [In Polish].
  24. Sellner J, Kraus J, Awad A, Milo R, Hemmer B, Stuve O. The increasing incidence and prevalence of female multiple sclerosis--a critical analysis of potential environmental factors. Autoimmun Rev 2011; 10(8): 495-502.
  25. Cooper GS, Bynum ML, Somers EC. Recent insights in the epidemiology of autoimmune diseases: Improved prevalence estimates and understanding of clustering of diseases. J Autoimmun 2009; 33(3-4): 197-207.
  26. Langer-Gould A, Albers KB, Van Den Eeden SK, Nelson LM. Autoimmune diseases prior to the diagnosis of multiple sclerosis: A population-based case-control study. Mult Scler 2010; 16(7): 855-61.
  27. Nielsen NM, Westergaard T, Frisch M, Rostgaard K, Wohlfahrt J, Koch-Henriksen N, et al. Type 1 diabetes and multiple sclerosis: A Danish population-based cohort study. Arch Neurol 2006; 63(7): 1001-4.
  28. Sloka JS, Phillips PW, Stefanelli M, Joyce C. Co-occurrence of autoimmune thyroid disease in a multiple sclerosis cohort. J Autoimmune Dis 2005; 2: 9.
  29. Munteis E, Cano JF, Flores JA, Martinez-Rodriguez JE, Miret M, Roquer J. Prevalence of autoimmune thyroid disorders in a Spanish multiple sclerosis cohort. Eur J Neurol 2007; 14(9): 1048-52.
  30. Broadley SA, Deans J, Sawcer SJ, Clayton D, Compston DA. Autoimmune disease in first-degree relatives of patients with multiple sclerosis. A UK survey. Brain 2000; 123 (Pt 6): 1102-11.
  31. Anaya JM. Autoimmunity and autoimmune disease: A Colombian construction beyond deconstructions. Autoimmun Rev 2006; 5(3): 165-6.
  32. Nageeb RS, Omran AA, Nageeb GS, Yousef MA, Mohammad YAA, Fawzy A. STAT4 gene polymorphism in two major autoimmune diseases (multiple sclerosis and juvenile onset systemic lupus erythematosus) and its relation to disease severity. Egypt J Neurol Psychiatr Neurosurg 2018; 54(1): 16.
  33. Heinzlef O, Alamowitch S, Sazdovitch V, Chillet P, Joutel A, Tournier-Lasserve E, et al. Autoimmune diseases in families of French patients with multiple sclerosis. Acta Neurol Scand 2000; 101(1): 36-40.
  34. Marrie RA, Rudick R, Horwitz R, Cutter G, Tyry T, Campagnolo D, et al. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology 2010; 74(13): 1041-7.